

Recommendation 6

The expert panel suggests either a strategy of screen with an HPV test followed by VIA and treat with cryotherapy (or LEEP when not eligible for cryotherapy) or a strategy of screen with an HPV test and treat with cryotherapy (or LEEP when not eligible) (conditional recommendation, ⊕⊕⊕⊕ evidence)


Remarks: The reductions in cancer and related mortality were greater with an HPV test used as a single screening test than with an HPV test followed by VIA, and this reduction was even greater in women of HIV-positive status. However, there may be overtreatment, and thus potentially greater harms with screen-and-treat when using an HPV test as a single test. There is also some uncertainty about the effects of an HPV test followed by VIA and how VIA performs after a positive HPV test because there was no direct evidence about this strategy. There is also the potential for additional resources that are required to refer women for VIA testing after a positive HPV test, the need for a second visit to perform VIA, and increased training to perform both tests. For these reasons, the recommendation is for either an HPV test followed by VIA or an HPV test only, and it is conditional. It is to be noted that benefits are more pronounced compared to harms in women of HIV-positive status when using an HPV test only.

Evidence-to-recommendation table

Decision domain	Judgement	Summary of reason for judgement				
Quality of evidence <i>Is there high- or moderate-quality evidence?</i>	<table border="1"> <tr> <td>Yes</td> <td>No</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </table>	Yes	No	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>There is low-quality evidence for the diagnostic test accuracy of HPV test followed by VIA and compared to HPV test alone. There is low- to very-low-quality evidence for the effects of treatment and the natural progression of CIN from observational studies often with inconsistent results across studies. The link between test accuracy data and treatment effects is very uncertain.</p>
Yes	No					
<input type="checkbox"/>	<input checked="" type="checkbox"/>					
Balance of benefits versus harms and burdens <i>Are you confident that the benefits outweigh the harms and burdens for the recommended strategy?</i>	<table border="1"> <tr> <td>Yes</td> <td>No</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </table>	Yes	No	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>There may be fewer major harms with HPV test followed by VIA than with HPV test alone due to less overtreatment. There may also be slightly greater cancers detected with HPV test followed by VIA than with HPV test alone. However, there may be slightly greater CIN recurrence, cervical cancer, and related mortality with HPV test followed by VIA.</p> <p>In women of HIV-positive status there were still fewer harms, less overtreatment and greater cancers detected at first-time screening. However, there was even greater CIN recurrence, cervical cancer and related mortality with HPV test followed by VIA in women of HIV-positive status than in women of unknown status.</p>
Yes	No					
<input type="checkbox"/>	<input checked="" type="checkbox"/>					
Values and preferences <i>Are you confident about the assumed or identified relative values and are they similar across the target population?</i>	<table border="1"> <tr> <td>Yes</td> <td>No</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	Yes	No	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>High value was placed on a screen-and-treat strategy versus no screening, since qualitative studies have shown that once women decide to be screened they find the screening tests and immediate treatment acceptable. High value was also placed on reducing overtreatment and resulting complications, and resource use.</p>
Yes	No					
<input checked="" type="checkbox"/>	<input type="checkbox"/>					
Resource implications <i>Is the cost small relative to the net benefits for the recommended strategy?</i>	<table border="1"> <tr> <td>Yes</td> <td>No</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </table>	Yes	No	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>Greater resources may be required for HPV test followed by VIA due to adding on an additional test. However, there is less overtreatment (fewer treatments provided) and fewer complications requiring hospitalization.</p>
Yes	No					
<input type="checkbox"/>	<input checked="" type="checkbox"/>					

Evidence for an HPV test followed by VIA compared to an HPV test to screen for CIN2+

1. Flowchart of screen-and-treat strategies



*Outcomes are: mortality from cervical cancer, rate of cervical cancer detection, rate of CIN2+ detection, major bleeding, premature delivery, infertility, STI detection, major infections, and minor infections

2. Evidence used for decision-making: HPV test followed by VIA compared to HPV test

Diagnostic test accuracy

Pooled sensitivity HPV test	95% (95% CI: 84 to 98)	Pooled sensitivity VIA	69% (95% CI: 54 to 81)
Pooled specificity HPV test	84% (95% CI: 72 to 91)	Pooled specificity VIA	87% (95% CI: 79 to 92)

2.1 Diagnostic test accuracy (DTA) evidence profile

Outcome	No. of studies (No. of patients)	Study design	Factors that may decrease quality of evidence					DTA QoE	Effect per 1000 patients/year for pretest probability of 5%		Importance
			Limitations	Indirectness	Inconsistency	Imprecision	Publication bias		HPV test followed by VIA	HPV test	
True positives (patients with CIN2+)	5 studies (8921 patients)	Cross-sectional and cohort studies	None ^a	None ^b	Serious ^c	None	Undetected	⊕⊕⊕⊕ moderate	13	19 (17 to 20)	CRITICAL
TP absolute difference									6 fewer		
True negatives (patients without CIN2+)	5 studies (8921 patients)	Cross-sectional and cohort studies	None ^a	None ^b	Serious ^c	None ^d	Undetected	⊕⊕⊕⊕ moderate	960	823 (706 to 892)	CRITICAL
TN absolute difference									137 more		
False positives (patients incorrectly classified as having CIN2+)	5 studies (8921 patients)	Cross-sectional and cohort studies	None ^a	None ^b	Serious ^c	None ^d	Undetected	⊕⊕⊕⊕ moderate	20	157 (88 to 274)	CRITICAL
FP absolute difference									137 fewer		
False negatives (patients incorrectly classified as not having CIN2+)	5 studies (8921 patients)	Cross-sectional and cohort studies	None ^a	None ^b	Serious ^c	None	Undetected	⊕⊕⊕⊕ moderate	7	1 (0 to 3)	CRITICAL
FN absolute difference									6 more		

Footnotes:

- ^a We used QUADAS to assess risk of bias. Many studies only performed one biopsy of an abnormal lesion. The decision to downgrade was a borderline judgement and was considered in the context of other factors.
- ^b Data for HPV test followed by VIA were calculated based on sensitivity and specificity of the two tests. Direct data were unavailable.
- ^c Estimates of HPV test and VIA sensitivity and specificity were variable despite similar cut-off values; inconsistency could not be explained by quality of studies. This was downgraded. This judgement was considered in the context of other factors, in particular imprecision.
- ^d Wide CI for HPV test sensitivity and VIA specificity, and therefore wide CI for TP, TN, FP, FN, may lead to different decisions depending on which confidence limits are assumed.

2.2 GRADE evidence table for patient-important outcomes following different screen-and-treat strategies: HPV test followed by VIA compared to HPV test

Outcomes	Events in the screen-and-treat strategies for patient-important outcomes (numbers presented per 1 000 000 patients)						
	HPV→VIA +/- CKC	HPV→VIA +/- LEEP	HPV→VIA +/- cryo	HPV +/- CKC	HPV +/- LEEP	HPV +/- cryo	No screen ¹⁰
Mortality from cervical cancer¹	91	99	99	20	30	30	250
Cervical cancer incidence²	128	138	138	28	43	43	350
CIN2+ recurrence³	4905	5311	5311	1088	1677	1677	13 400
Undetected CIN2+ (FN)	7000			1000			–
Major bleeding⁴	288	76	11	1511	397	60	0
Premature delivery⁵	540	514	521	712	575	610	500
Infertility⁶	–	–	–	–	–	–	–
Major infections⁷	30	43	5	156	225	24	0
Minor infections⁸	314	202	217	1649	1061	1139	0
Unnecessarily treated (FP)	20 000			157 000			–
Cancer found at first-time screening⁹	3168			2454			0

Footnotes:

The colours in the table: In each GRADE evidence table, colour-coding is used to highlight the 'desirability' of the effects for that outcome relative to other outcomes. The continuum runs from dark gray (desirable) through light gray and light pink to dark pink (least desirable).

The numbers in the table are based on

- CIN2+ pretest probability 2%
- VIA: pooled sensitivity 69% (95% CI: 54 to 81), pooled specificity 87% (95% CI: 79 to 92)
- HPV test: pooled sensitivity 95% (95% CI: 84 to 98), pooled specificity 84% (95% CI: 72 to 91)
- The overall QoE for each of these outcomes is very low ⊕⊕⊕⊕. Our lack of confidence in these effect estimates stems mainly from very low-quality evidence for treatment effects and natural progression/history data.

- ¹ We assume no mortality from cervical cancer in TN and FP. To calculate the mortality from cervical cancer, we assumed 250 deaths per 350 women with cervical cancer. These numbers are based on Eastern Africa age-standardized rates of cervical cancer and mortality provided by WHO (<http://globocan.iarc.fr/>, accessed 30 October 2012).
- ² We assume no cervical cancer in TN or FP. To calculate cervical cancer incidence in women with persistent CIN2+, we assumed 350 cervical cancers per 14 000 women who have persistent CIN2+ (i.e. FN). This incidence is based on Eastern Africa age-standardized rate of cervical cancer of 350 cervical cancers per 1 000 000 women, of whom 2% have CIN2+ (20 000 women with CIN2+, and a subsequent 30% regression for a total of 14 000 with persistent CIN2+). These data are available from WHO (<http://globocan.iarc.fr/>, accessed 30 October 2012).
- ³ We assume no CIN2+ in TN and FP. Our calculations in the model are based on 70% natural persistence of CIN2+ with no treatment (30% regression) in FN. The incidence of cervical cancer and mortality are also subtracted from the CIN2+ in FN (see above for calculations). TP are treated and recurrence rates of CIN2+ are 5.3% in cryotherapy and LEEP, and 2.2% in CKC.
- ⁴ We assumed major bleed would be 0 in TN and FN as they were not treated. We assumed 0.000339 of the population treated with cryotherapy, 0.002257 with LEEP, and 0.001705 with CKC, based on pooled proportions in observational studies with no independent controls, will have major bleeding.
- ⁵ We assumed 5% population risk of premature delivery in 1% of women who become pregnant. Based on pooled meta-analysis of controlled observational studies, 0.001125 of the population treated with cryotherapy, 0.000925 with LEEP, and 0.001705 of the population treated with CKC will have premature delivery.
- ⁶ We did not identify any data about the risk of infertility after treatment for CIN2+.
- ⁷ We assumed major infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control 0.000135 of the population treated with cryotherapy 0.001279 with LEEP, and 0.000888 with CKC will have major infection.
- ⁸ We assumed minor infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control, 0.006473 of the population treated with cryotherapy, 0.006027 with LEEP, and 0.009368 with CKC will have minor infection.
- ⁹ Cancers detected at first-time screening calculated from Sankaranarayanan et al. (2005). Numbers for single screening tests were calculated as 'screen-detected' cancers in women who participated in the screening programme; and numbers for test with colposcopy were calculated as 'screen-detected' plus 'clinically detected' cancers. For a sequence of tests (e.g. HPV test followed by VIA), the greater number of cancers detected between tests was used. No cancers would be found in the 'no screen' group. This is not the annual incidence of cervical cancer (which is shown in a row above). It represents the cumulative rate of cancer development before screening started (i.e. the prevalence of cancer at the time when screening is conducted).
- ¹⁰ 'No screen' numbers were calculated using the same assumptions above for FN, with the exception of premature delivery which was baseline risk in the population.

2.3 GRADE evidence table for patient-important outcomes following different screen-and-treat strategies by age

	HPV→VIA +/- CKC	HPV→VIA +/- LEEP	HPV→VIA +/- cryo	HPV +/- CKC	HPV +/- LEEP	HPV +/- cryo	No screen ¹⁰
15–39 years^a							
Mortality from cervical cancer	26	28	28	6	9	9	71
Cervical cancer incidence	37	39	39	8	12	12	100
CIN2+ recurrence	5052	5459	5459	1109	1698	1698	13 829
40–49 years^a							
Mortality from cervical cancer	170	183	183	37	57	57	464
Cervical cancer incidence	237	256	256	52	79	79	650
CIN2+ recurrence	4728	5134	5134	1062	1651	1651	12 886
50–74 years^a							
Mortality from cervical cancer	313	338	338	68	105	105	857
Cervical cancer incidence	438	473	473	96	146	146	1200
CIN2+ recurrence	4403	4809	4809	1015	1604	1604	11 943
Complications (same across all groups)							
Major bleeding ⁴	288	76	11	1511	397	60	0
Premature delivery ⁵	540	514	521	712	575	610	500
Infertility ⁶	–	–	–	–	–	–	–
Major infections ⁷	30	43	5	156	225	24	0
Minor infections ⁸	314	202	217	1649	1061	1139	0

Footnotes:

^a Events were calculated similar to Table 2.2. However, events for cervical cancer are based on incidence of cervical cancer in Eastern Africa of 100/1 000 000 cervical cancers per year in women age 15–39 years; 650 for age 40–49 years; and 1200 for age 50–74 years, provided by WHO (<http://globocan.iarc.fr/>, accessed 30 October 2012). It is assumed that the recurrence of CIN is constant across age groups but the incidence of cervical cancer and associated mortality increases, thus reducing the overall recurrence of CIN (a proportion of those with CIN will develop cancer or die). These data should be used primarily to make comparisons across screen-and-treat strategies, not within columns for different age groups.

^{4,5,6,7,8,10} See footnotes for Table 2.2.

3. References to studies included in meta-analysis of diagnostic test accuracy

Belinson J et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. *Gynecologic Oncology*, 2001, 83(2):439–444.

De Vuyst H et al. Comparison of Pap smear, visual inspection with acetic acid, human papillomavirus DNA–PCR testing and cervicography. *International Journal of Gynecology & Obstetrics*, 2005, 89(2):120–126.

Pan Q et al. A thin-layer, liquid-based Pap test for mass screening in an area of China with a high incidence of cervical carcinoma: a cross-sectional, comparative study. *Acta Cytologica*, 2003, 47(1):45–50.

Qiao YL et al. A new HPV–DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. *Lancet Oncology*, 2008, 9(10):929–936.

Shastri SS et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. *Bulletin of the World Health Organization*, 2005, 83(3):186–194.

Sodhani P et al. Test characteristics of various screening modalities for cervical cancer: a feasibility study to develop an alternative strategy for resource-limited settings. *Cytopathology*, 2006, 17(6):348–352.